Skip to main content

Table 1 Baseline demographics and clinical characteristics (ITT population)

From: A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

   Revefenacin  
  Placebo
(n = 70)
44 μg
(n = 68)
88 μg
(n = 71)
175 μg
(n = 71)
350 μg
(n = 74)
Total
(N = 354)
Age (years)
 Mean (SD) 62.2 (9.17) 60.9 (8.87) 60.4 (7.98) 64.5 (7.69) 61.4 (8.98) 61.9 (8.63)
Sex (%)
 Male 37 (52.9) 32 (47.1) 32 (45.1) 37 (52.1) 40 (54.1) 178 (50.3)
 Female 33 (47.1) 36 (52.9) 39 (54.9) 34 (47.9) 34 (45.9) 176 (49.7)
Race (%)
 White 65 (92.9) 63 (92.6) 64 (90.1) 65 (91.5) 67 (90.5) 324 (91.5)
 Black/African American 4 (5.7) 4 (5.9) 6 (8.5) 5 (7.0) 6 (8.1) 25 (7.1)
 Other 1 (1.4) 1 (1.5) 1 (1.4) 1 (1.4) 1 (1.4) 5 (1.4)
BMI (kg/m2)
 Mean (SD) 27.6 (5.73) 27.9 (6.87) 27.0 (5.92) 28.0 (5.30) 29.0 (5.76) 27.9 (5.93)
Current smoker (%)
 Yes 35 (50.0) 40 (58.8) 44 (62.0) 33 (46.5) 38 (51.4) 190 (53.7)
Smoking duration (pack-years)
 Mean (SD) 38.2 (9.71) 39.3 (11.59) 38.9 (10.16) 41.2 (10.01) 39.6 (9.04) 39.5 (10.11)
Current ICS use (%)
 Yes 29 (41.4) 25 (36.8) 24 (33.8) 26 (36.6) 26 (35.1) 130 (36.7)
Pre-dose FEV1 (mL)
 Mean (SD) 1205.0 (473.00) 1279.0 (470.10) 1321.0 (441.58) 1267.2 (415.67) 1338.8 (483.95) 1282.6 (457.25)
Pre-dose FEV1/FVC (%)
 n 70 68 71 71 72 352
 Mean (SD) 0.50 (0.11) 0.51 (0.11) 0.52 (0.09) 0.51 (0.10) 0.52 (0.09) 0.51 (0.10)
Percent predicted post-bronchodilator FEV1 (%)
 n 70 68 71 71 72 352
 Mean (SD) 41.2 (13.00) 43.0 (13.35) 45.1 (12.43) 44.0 (11.76) 44.5 (12.35) 43.6 (12.58)
  1. Abbreviations: BMI body mass index, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, ITT intent to treat, SD standard deviation